Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F.
Guglielmi C, et al. Among authors: gisselbrecht c.
J Clin Oncol. 1998 Oct;16(10):3264-9. doi: 10.1200/JCO.1998.16.10.3264.
J Clin Oncol. 1998.
PMID: 9779700
Clinical Trial.